SPYRE THERAPEUTICS, INC.: cash_and_restricted_cash
| Value | {"amount": 89423000, "concept": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "currency": "USD"} |
|---|---|
| Period | (as of 2024-12-31) |
| Status | current |
| Entity | SPYRE THERAPEUTICS, INC. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T16:49:38.245373+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/4a9b7ea6-dcca-4c0c-b202-e4ef05b84f89
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001636282-25-000020 · Open the official SEC filing →Retrieved: 2026-08-19T16:49:38.245373+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001636282/cash-and-restricted-cash/2024-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/4a9b7ea6-dcca-4c0c-b202-e4ef05b84f89
History
- no predecessors — first report